Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 July 2026, providing investors with the latest insights into its performance and outlook.

Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a shift in its technical momentum from sideways to mildly bearish. Despite some bullish signals on weekly indicators, monthly trends and moving averages suggest caution for investors as the stock price declined by 1.63% on 14 Jul 2026, closing at ₹33.89.

Shukra Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 July 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd has experienced a notable shift in price momentum, reflected in a complex interplay of technical indicators that suggest a transition from a mildly bearish trend to a sideways movement. Despite a strong intraday gain of 4.78%, the stock’s technical landscape remains nuanced, with weekly and monthly signals diverging across key metrics such as MACD, RSI, Bollinger Bands, and moving averages.

Shukra Pharmaceuticals Ltd has experienced a notable shift in price momentum, reflected in a 7.57% gain on 6 July 2026, signalling a potential change in market sentiment. Despite this short-term strength, technical indicators present a nuanced picture, with several metrics suggesting a cautiously bearish outlook amid mixed signals from key oscillators and moving averages.

Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Shukra Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 17 June 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, prompting a downgrade in its Mojo Grade from Hold to Sell as of 30 April 2026. The stock’s recent price action and technical indicators suggest increasing bearish pressure, with the share price retreating 3.42% on 10 June 2026 to close at ₹30.78, down from the previous close of ₹31.87.

Shukra Pharmaceuticals Ltd has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a modest daily price increase of 1.30%, the stock’s technical indicators reveal a nuanced momentum change, prompting a downgrade in its Mojo Grade from Hold to Sell as of 30 April 2026.

Shukra Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd. reported a challenging fourth quarter for FY26, with net profit swinging to a loss of ₹1.72 crores from a profit of ₹5.39 crores in the same period last year, marking a sharp 154.43% year-on-year decline. The micro-cap pharmaceutical company, with a market capitalisation of ₹1,469 crores, saw its stock decline 4.99% to ₹33.54 following the results announcement, as investors reacted to the dramatic quarterly reversal despite strong half-yearly performance.

Shukra Pharmaceuticals Ltd has experienced a notable shift in its financial trend, moving from an outstanding to a positive performance rating in the latest quarter ending March 2026. Despite strong half-yearly sales and profit after tax (PAT) figures, the company’s most recent quarterly results reveal significant declines in revenue and profitability compared to its previous four-quarter averages, prompting a downgrade in its Mojo Grade from Hold to Sell.

Shukra Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a shift in its technical momentum, moving from a mildly bearish to a bearish trend. Despite a modest day change of 0.03%, the stock’s technical indicators reveal a complex picture with mixed signals across weekly and monthly timeframes, prompting a downgrade in its Mojo Grade from Hold to Sell as of 30 April 2026.